Gene expression profiling weighs heavily in decisions for breast cancer patients yet poorly understood
Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to receive chemotherapy. However, many of the patients do not fully understand what some of the test results mean, new research has suggested.
Current guidelines for treating early-stage breast cancer, with no metastasis to nearby lymph nodes or other parts of the body, result in thousands of women receiving chemotherapy without benefitting from it.
A gene expression profiling (GEP) test can help differentiate women who might benefit from chemotherapy versus those that might not. The test analyzes the patterns of 21 different genes within the cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.
Yvonne Bombard, PhD, a genomics and health services researcher in the Li Ka Shing Knowledge Institute of St. Michael's Hospital in Toronto, Ontario, Canada, said women she interviewed understood the test would indicate whether chemotherapy would be beneficial to them.
However, Bombard said, many thought the test reflected their unique circumstances and did not understand that their test result was based on larger population statistics. Her findings have been published online in Current Oncology (2014; doi:10.3747/co.21.1524).
“Patients often viewed their GEP results as providing information that was more scientifically valid, uniquely personalized, and emotionally significant than any other information they had received,” Bombard said. “For many, the test was a transformational element that empowered them, allowed them to feel confident in their decisions, and may even have rescued them from unnecessary chemotherapy.”
The GEP test was a main determinant of patients' chemotherapy decisions, despite their misunderstanding of the test and its validity.
“GEP is one of many factors that women in consultation with their oncologists, should consider when choosing treatment for early stage breast cancer,” said study co-author Maureen Trudeau, MA, MD, FRCPC, a medical oncologist of the Breast Care team and head of the Medical Oncology Program at Sunnybrook's Odette Cancer Centre at the University of Toronto. “The GEP test does not replace standard prognostic information but adds one more piece of information.”
Clinical guidelines suggest the majority of the 22,600 Canadians whose breast cancer tests negative for human epidermal growth factor receptor 2 (HER2) should be offered chemotherapy. Yet only 15% of such cancers will recur, suggesting that about 8,500 Canadian patients are treated without benefit each year.